147 related articles for article (PubMed ID: 7741492)
1. Randomised study comparing imipenem/cilastatin to ceftriaxone plus gentamicin in cancer chemotherapy-induced neutropenic fever.
Au E; Tow A; Allen DM; Ang PT
Ann Acad Med Singap; 1994 Nov; 23(6):819-22. PubMed ID: 7741492
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ceftazidime or imipenem/cilastatin versus ceftriaxone + aminoglycoside in the treatment of febrile episodes in neutropenic cancer patients in Germany.
Dietrich ES; Patz E; Frank U; Daschner FD
Infection; 1999; 27(1):23-7. PubMed ID: 10027102
[TBL] [Abstract][Full Text] [Related]
3. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders.
Engervall PA; Stiernstedt GT; Günther GC; Björkholm MJ
J Chemother; 1992 Apr; 4(2):99-106. PubMed ID: 1629753
[TBL] [Abstract][Full Text] [Related]
4. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
Liu CY; Wang FD
Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
[TBL] [Abstract][Full Text] [Related]
6. Fever and neutropenia in children with cancer: a therapeutic approach related to the underlying disease.
Petrilli AS; Melaragno R; Barros KV; Silva AA; Kusano E; Ribeiro RC; Bianchi A
Pediatr Infect Dis J; 1993 Nov; 12(11):916-21. PubMed ID: 8265281
[TBL] [Abstract][Full Text] [Related]
7. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
[TBL] [Abstract][Full Text] [Related]
8. A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients.
Kojima A; Shinkai T; Soejima Y; Okamoto H; Eguchi K; Sasaki Y; Tamura T; Oshita F; Ohe Y; Saijo N
Am J Clin Oncol; 1994 Oct; 17(5):400-4. PubMed ID: 8092111
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].
Figuera A ; Rivero N; Pajuelo F; Font P; Leyra F; de La Cámara R; Arranz R; María Fernández Rañada J
Med Clin (Barc); 2001 May; 116(16):610-1. PubMed ID: 11412645
[TBL] [Abstract][Full Text] [Related]
10. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.
Gorschlüter M; Hahn C; Fixson A; Mey U; Ziske C; Molitor E; Horré R; Sauerbruch T; Marklein G; Schmidt-Wolf IG; Glasmacher A
Support Care Cancer; 2003 Jun; 11(6):362-70. PubMed ID: 12690546
[TBL] [Abstract][Full Text] [Related]
11. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.
Liang R; Yung R; Chiu E; Chau PY; Chan TK; Lam WK; Todd D
Antimicrob Agents Chemother; 1990 Jul; 34(7):1336-41. PubMed ID: 2201252
[TBL] [Abstract][Full Text] [Related]
13. Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.
Ozyilkan O; Yalçintaş U; Başkan S
Korean J Intern Med; 1999 Jul; 14(2):15-9. PubMed ID: 10461420
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of the cost-effectiveness of initial therapy with imipenem/cilastatin in secondary peritonitis].
Rodloff AC; Kujath P; Lünstedt B; Gaus W
Chirurg; 1998 Oct; 69(10):1093-100; discussion 1100. PubMed ID: 9833192
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of imipenem-cilastatin versus gentamicin plus clindamycin in the treatment of polymicrobial infections.
Danziger LH; Creger RJ; Shwed JA; Stellato TA; Hau T
Pharmacotherapy; 1988; 8(6):315-8. PubMed ID: 3222164
[TBL] [Abstract][Full Text] [Related]
16. Imipenem/cilastatin monotherapy as salvage treatment in febrile neutropenic patients.
Engervall P; Günther G; Ljungman P; Lönnqvist B; Hast R; Stiernstedt G; Kalin M; Ringertz S; Björkholm M
J Chemother; 1996 Oct; 8(5):382-6. PubMed ID: 8957719
[TBL] [Abstract][Full Text] [Related]
17. Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study.
Norrby SR; Eriksson M; Ottosson E
Scand J Infect Dis; 1986; 18(4):371-4. PubMed ID: 3094139
[TBL] [Abstract][Full Text] [Related]
18. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V
J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553
[TBL] [Abstract][Full Text] [Related]
19. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.
Karadeniz C; Oğuz A; Canter B; Serdaroğlu A
Pediatr Hematol Oncol; 2000; 17(7):585-90. PubMed ID: 11033734
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients.
Mortimer J; Miller S; Black D; Kwok K; Kirby WM
Am J Med; 1988 Jul; 85(1A):17-20. PubMed ID: 3400679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
